Healthcare remained a top priority for antitrust enforcers in the first half of 2026 as federal and state regulators remained active through a range of enforcement actions and policy initiatives. The FTC’s newly launched Healthcare Task Force signals sustained, coordinated scrutiny of both healthcare deals and commercial arrangements. Sevita/BrightSpring and Ascension/AmSurg confirm the FTC’s continued preference for facility divestitures over blocking transactions outright.
Read the full article: Antitrust & Competition Healthcare 1H 2026 Update //
Source: https://www.goodwinlaw.com/en/insights/publications/2026/07/insights-practices-hltc-antitrust-competition-healthcare-1h-2026-update